With the persistent and ongoing threat of the coronavirus pandemic, infection prevention and establishment of herd immunity is a top priority, necessitating the continued development of COVID-19 vaccines that are inexpensive and easy to distribute across the globe. Developing successful and effective vaccines requires evaluating host immune responses to the virus in large study groups. In support of these efforts, RayBiotech provides a versatile range of reagents and kits to address the need for detection of SARS-CoV-2 antigens, monitoring immunoreactivity, and titering viral neutralizing antibodies in patient specimens.
To address the need for viral protein detection in patient samples, we provide high quality immunoreagents for ELISA development as well as finished kits.
A critical molecular event in COVID-19 infection is the interaction between the viral spike RBD (S1 RBD) and the receptor on the human epithelial cell surface, which mediates cellular invasion by the virus. Thus, neutralizing antibodies (nAbs) which can block this interaction are an important defense against future SARS-CoV-2 infections.
The detection of nAbs is a key indicator that protective immunity has been established. In vaccine efficacy trials, efficient methods of nAb titering are needed. We have developed a series of in vitro binding assays which allow not only the rapid screening of patient sera for nAbs but can also validate inhibitors of SARS-CoV-2 infectivity.
The S1 RBD may bind to several different host cell surface receptors, including ACE2 and neuropilin-1. The RayBio COVID-19 Spike-ACE2 and Spike-NRP1 Binding Assay Kits are plate-based colorimetric assays for measuring neutralizing activity of antibodies, sera, or other inhibitors.
RayBiotech's COVID-19 pseudovirus service enables the study of the SARS-CoV-2 virus in cell culture. This service is ideal for:
RayBiotech provides tools to help you monitor COVID-19 vaccine effectiveness, including validated antibodies, proteins, and ready-to-use kits for detection of immunoreactivity with SARS-CoV-2 antigens.
Antibody screening has an important role in determining immunity to and prevalence of COVID-19, as well as identifying who has been infected and evaluating potential blood-based therapeutics. Indirect ELISA (iELISA) is a reliable, powerful technique for determining total antibody concentrations in a sample.
RayBiotech's range of anti-SARS-CoV-2 antibodies includes monoclones that are validated as iELISA positive controls, allowing for rapid development and calibration of your diagnostic immunoassays. The product range also includes clones with SARS-CoV-2 neutralizing activity.
RayBiotech has an extensive catalog of recombinant SARS-CoV-2 antigens, including nucleocapsid, spike domains, and membrane protein. Choosing one or a mixture of viral components allows you to tailor an antibody screening assay to your needs.
Patient samples enable the measurement of cellular and humoral immune responses to COVID-19 infection or COVID-19 vaccination. RayBiotech offers serum, plasma, dried blood spots, and peripheral blood mononuclear cells (PBMCs) samples from a variety of patients to accelerate COVID-19 vaccine development.
Samples collected before the outbreak of COVID-19, thus these samples were taken from patients who were not infected with COVID-19.
Samples collected from patients confirmed to have COVID-19 via a SARS-CoV-2 nucleic acid-, antibody-, or antigen-based test.
Samples collected from patients who received an FDA-approved vaccine.